Beta Drugs Financial Statements
Beta Drugs Quarterly Results
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar | Mar-2021 | Mar-2020 | - | - |
|---|---|---|---|---|
| Growth matrix (%) | ||||
| Revenue growth | 27.90 | -- | -- | -- |
| Op profit growth | 38.20 | -- | -- | -- |
| EBIT growth | 26.20 | -- | -- | -- |
| Net profit growth | 24.50 | -- | -- | -- |
| Profitability ratios (%) | ||||
| OPM | 21.30 | 19.70 | -- | -- |
| EBIT margin | 15.80 | 16 | -- | -- |
| Net profit margin | 10.10 | 10.40 | -- | -- |
| RoCE | 22.20 | -- | -- | -- |
| RoNW | 4.66 | -- | -- | -- |
| RoA | 3.54 | -- | -- | -- |
| Per share ratios () | ||||
| EPS | 12.20 | 9.79 | -- | -- |
| Dividend per share | -- | -- | -- | -- |
| Cash EPS | 5.05 | 5.88 | -- | -- |
| Book value per share | 71.40 | 59.40 | -- | -- |
| Valuation ratios | ||||
| P/E | 9.84 | 4.09 | -- | -- |
| P/CEPS | 23.80 | 6.80 | -- | -- |
| P/B | 1.68 | 0.67 | -- | -- |
| EV/EBIDTA | 4.85 | 3.04 | -- | -- |
| Payout (%) | ||||
| Dividend payout | -- | -- | -- | -- |
| Tax payout | (26) | (21) | -- | -- |
| Liquidity ratios | ||||
| Debtor days | 103 | -- | -- | -- |
| Inventory days | 44.60 | -- | -- | -- |
| Creditor days | (76) | -- | -- | -- |
| Leverage ratios | ||||
| Interest coverage | (7.60) | (5.60) | -- | -- |
| Net debt / equity | 0.10 | 0.30 | -- | -- |
| Net debt / op. profit | 0.28 | 0.96 | -- | -- |
| Cost breakup () | ||||
| Material costs | (51) | (49) | -- | -- |
| Employee costs | (9.40) | (10) | -- | -- |
| Other costs | (19) | (21) | -- | -- |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | - | - |
|---|---|---|---|---|
| Revenue | 116 | 90.80 | -- | -- |
| yoy growth (%) | 27.90 | -- | -- | -- |
| Raw materials | (59) | (44) | -- | -- |
| As % of sales | 50.60 | 48.80 | -- | -- |
| Employee costs | (11) | (9.50) | -- | -- |
| As % of sales | 9.37 | 10.40 | -- | -- |
| Other costs | (22) | (19) | -- | -- |
| As % of sales | 18.70 | 21 | -- | -- |
| Operating profit | 24.70 | 17.90 | -- | -- |
| OPM | 21.30 | 19.70 | -- | -- |
| Depreciation | (6.90) | (3.80) | -- | -- |
| Interest expense | (2.40) | (2.60) | -- | -- |
| Other income | 0.50 | 0.41 | -- | -- |
| Profit before tax | 16 | 12 | -- | -- |
| Taxes | (4.20) | (2.60) | -- | -- |
| Tax rate | (26) | (21) | -- | -- |
| Minorities and other | -- | -- | -- | -- |
| Adj. profit | 11.70 | 9.42 | -- | -- |
| Exceptional items | -- | -- | -- | -- |
| Net profit | 11.70 | 9.42 | -- | -- |
| yoy growth (%) | 24.50 | -- | -- | -- |
| NPM | 10.10 | 10.40 | -- | -- |
- Switch to
-
Tabular DataGraph
| Y/e 31 Mar ( In .Cr) | Mar-2021 | Mar-2020 | - | - |
|---|---|---|---|---|
| Profit before tax | 16 | 12 | -- | -- |
| Depreciation | (6.90) | (3.80) | -- | -- |
| Tax paid | (4.20) | (2.60) | -- | -- |
| Working capital | 8.86 | -- | -- | -- |
| Other operating items | -- | -- | -- | -- |
| Operating cashflow | 13.70 | -- | -- | -- |
| Capital expenditure | 2.85 | -- | -- | -- |
| Free cash flow | 16.60 | -- | -- | -- |
| Equity raised | 94.80 | -- | -- | -- |
| Investments | 0.43 | -- | -- | -- |
| Debt financing/disposal | (5.10) | -- | -- | -- |
| Dividends paid | -- | -- | -- | -- |
| Other items | -- | -- | -- | -- |
| Net in cash | 107 | -- | -- | -- |
- Switch to
-
Tabular DataGraph
- Switch to
-
ConsolidatedStandalone
| Y/e 31 Mar ( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
| Equity capital | 9.61 | 9.61 | 8.65 | 8.65 |
| Preference capital | -- | -- | -- | -- |
| Reserves | 59 | 47.50 | 32.30 | 24.20 |
| Net worth | 68.60 | 57.10 | 40.90 | 32.90 |
| Minority interest | ||||
| Debt | 17.50 | 22.60 | 20 | 7.50 |
| Deferred tax liabilities (net) | -- | -- | 0.15 | 0.15 |
| Total liabilities | 86.10 | 79.70 | 61 | 40.50 |
| Fixed assets | 42.80 | 43.90 | 32.40 | 14.50 |
| Intangible assets | ||||
| Investments | 0.78 | 0.35 | 0.35 | -- |
| Deferred tax asset (net) | 0.65 | 0.17 | 0.29 | -- |
| Net working capital | 31.40 | 29.90 | 24.70 | 14.10 |
| Inventories | 16 | 12.40 | 9.53 | 2.80 |
| Inventory Days | 50.40 | 49.60 | -- | -- |
| Sundry debtors | 33.90 | 31.90 | 25 | 14.40 |
| Debtor days | 106 | 128 | -- | -- |
| Other current assets | 13 | 13.10 | 11.80 | 5.89 |
| Sundry creditors | (22) | (16) | (16) | (6.10) |
| Creditor days | 67.80 | 65.70 | -- | -- |
| Other current liabilities | (9.90) | (11) | (6.10) | (3) |
| Cash | 10.40 | 5.39 | 3.30 | 11.90 |
| Total assets | 86.10 | 79.70 | 61 | 40.50 |
- Switch to
-
ConsolidatedStandalone
| Beta Drugs Ltd Report not showing data |
|---|
QuickLinks for Beta Drugs Ltd.
Open a Demat Account & Get
Free Benefits worth ₹ 10,000
₹0
Delivery Brokerage for Lifetime
₹20
Per order for Intraday, F&O, Currency & Commodity
